Journal of Drugs in Dermatology
Generalized pustular psoriasis following withdrawal of efalizumab.
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
关键词
抽象
Efalizumab is one of the new biologic therapies targeting T-lymphocyte activity for the treatment of chronic plaque psoriasis. Common adverse effects include headaches, nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following discontinuation of the drug has been reported. Relapse events can manifest as recurrent plaque psoriasis, guttate psoriasis, psoriatic erythroderma, and pustular psoriasis. We report a second case of withdrawal flare resulting in generalized pustular psoriasis.